Clinical Trials Logo

Clinical Trial Summary

The study will observe and quantify shifts in colposcopy practice and outcome improvements in U.S. community-based cervical screening colposcopy examinations after the introduction of the DySIS colposcope with Advanced Cervical Scan.

The study will collect colposcopy data across multiple sites in two arms; a prospective arm, with DySIS being used for the examination and a retrospective arm, with data retrieved from patient charts.


Clinical Trial Description

Each site will contribute data to both arms; the study will collect data on demographics, disease yield, number of biopsies and treatment decisions. Study subjects will receive standard of care procedures and management.

Prospective data will be collected at colposcopy examinations performed using the DySIS digital colposcope on consecutive patients that have been referred for colposcopy after a positive screening test. Retrospective data on colposcopy examinations performed using a standard colposcope will be collected from patient medical records, to capture standard practice to-date as a control for comparisons. The retrospective data will be collected from consecutive examinations performed by the providers participating in the prospective arm and for the preceding year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02185599
Study type Observational
Source DySIS Medical Inc.
Contact
Status Completed
Phase
Start date September 2014
Completion date October 9, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03196180 - Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia Early Phase 1
Recruiting NCT05074264 - Screening Algorithms for Cervical and Anal High-Grade Squamous Intraepithelial Lesions in People With HIV in Mexico and Puerto Rico N/A
Recruiting NCT02406352 - Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia N/A
Completed NCT02529930 - An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) Phase 1/Phase 2